Schrödinger Earnings Call Transcripts
Fiscal Year 2026
-
The forum highlighted a validated computational platform driving molecule design, a strategic shift to hosted software contracts, and a focus on early toxicity prediction with new products like Predictive Tox. AI integration and improved funding environments are expected to fuel growth and industry partnerships.
-
The session detailed the transition to ACV for improved revenue visibility, highlighted robust partnership success, and addressed AI disruption concerns. New modules like predictive toxicology are set to drive growth, while materials science offers long-term potential.
-
The conference highlighted a successful transition to hosted services, with ACV as the key metric, and showcased advances in computational chemistry and AI that are accelerating drug discovery. Growth is expected from predictive toxicology, expanded platform capabilities, and strategic partnerships, while the therapeutics pipeline progresses through collaborations.
Fiscal Year 2025
-
Revenue grew 23% to $256M in 2025, with strong software and drug discovery performance and a robust $402M cash position. Transition to hosted software is underway, targeting 10%-15% ACV growth and positive adjusted EBITDA by 2028, despite near-term revenue volatility.
-
Physics-based computational platform drives growth through software, collaborations, and discovery, with $54M in quarterly revenue and a $250M annual target. Strategic shift to R&D focus, cost optimization, and partnerships aims to enhance profitability and pipeline value.
-
Q3 2025 saw 54% revenue growth, driven by software and drug discovery, with improved margins and reduced expenses. Guidance for software revenue was lowered due to delayed pharma opportunities, while drug discovery guidance increased. Strategic focus shifts to discovery-stage partnerships and operational efficiency.
-
The platform's physics-based approach enables scalable, efficient drug discovery, validated by multiple clinical-stage collaborations and strong customer retention. Regulatory shifts and strategic partnerships are accelerating adoption, while financial discipline and a focus on innovation support long-term growth.
-
Q2 2025 revenue grew 16% year-over-year to $54.8M, with software and drug discovery segments both expanding. Gross margin declined due to investment in predictive toxicology, while operating expenses and net loss improved. Guidance for 2025 is maintained, with strong cash reserves and continued pipeline progress.
-
The meeting covered board elections, executive compensation, and auditor ratification, with all proposals approved. Strategic priorities include advancing clinical programs, expanding the computational platform, and delivering new technologies. No questions were raised by shareholders.
-
SGR-1505 demonstrated a favorable safety profile and preliminary efficacy in heavily pretreated B-cell malignancy patients, including those resistant to BTK and BCL2 inhibitors. The program will advance to FDA discussions, with future plans focusing on combination strategies and potential partnerships.
-
Management highlighted strong Q1 software growth, robust cash position, and ongoing clinical progress, especially for the MALT1 and CDC7 programs. The predictive toxicology platform is in beta, with future revenue potential, and software adoption among large pharma remains a key focus.
-
The event highlighted strong software revenue growth, major new collaborations, and robust clinical progress, especially for SGR-1505. Platform enhancements align with regulatory trends, and the company’s unique technology positions it for further expansion in both software and drug discovery.
-
Q1 2025 saw 63% revenue growth year-over-year, driven by strong software and drug discovery performance, with a robust cash position and reaffirmed full-year guidance. Major software enhancements and progress in clinical programs position the company for continued momentum in 2025.
-
A 35-year-developed computational platform combining physics and AI is driving growth in software and drug discovery revenues, with major pharma collaborations and new initiatives in predictive toxicology and biologics. Three oncology programs will present clinical data in 2024.
-
The platform integrates physics-based and machine learning methods for accurate, scalable drug discovery, driving both software and drug discovery revenue growth. Industry adoption is expanding, with proprietary clinical programs advancing and significant room for further market penetration.
-
The platform integrates physics-based and machine learning methods for accurate, scalable molecular prediction, driving strong software and drug discovery revenue growth. Expanded partnerships and a robust clinical pipeline highlight ongoing innovation, with key data updates expected this year.
Fiscal Year 2024
-
2024 saw strong software growth, expanded collaborations, and new product launches, though total revenue declined due to lower drug discovery milestones. Guidance for 2025 anticipates 10–15% software growth, higher hosted revenue, and key clinical data readouts from three programs.
-
A leading computational drug discovery platform is driving growth through expanded pharma adoption, major collaborations like Novartis, and innovative products such as predictive toxicology. The proprietary pipeline is advancing, with key clinical data expected in 2025 and a flexible partnering strategy to maximize value.
-
A leading computational drug discovery platform is driving growth through software sales, pharma collaborations, and a proprietary clinical pipeline. Major new deals, including a $150M Novartis collaboration, and upcoming clinical data are expected to boost revenue and value creation.
-
Q3 2024 saw a major Novartis collaboration, $35.3M in revenue, and strong software growth, though total revenue declined year-over-year due to lower drug discovery revenue. Guidance for software revenue was raised, while drug discovery guidance was lowered, with significant contributions expected in 2025 from new deals.
-
Software adoption is accelerating due to cost savings and multi-parameter optimization in drug discovery, with strong 2024 financial guidance and a robust pipeline led by MALT1. The company expects a more balanced revenue mix and increased partnerships as the platform gains further validation.
-
Q2 2024 saw strong revenue growth, improved gross margins, and progress in clinical and software initiatives. Full-year guidance is reiterated, with continued high customer retention and new capital expected from asset sales and partnerships.
-
The meeting confirmed a quorum, approved all proposals including director elections and plan amendments, and ratified the auditor. Strategic priorities focus on expanding computational capabilities and advancing proprietary drug programs, with key clinical milestones anticipated this year.
-
Management highlighted a validated, physics- and AI-driven platform with strong software revenue, expanding SaaS adoption, and a robust proprietary drug pipeline. Clinical programs are advancing, with key data expected late 2024–2025, and financials remain solid despite milestone timing shifts.